iiinova — where your digital self keeps evolving

braincancerlab.bsky.social @braincancerlab.bsky.social · 03/11/2025

Excited to see the updated results from INDIGO confirming sustained benefit of mIDH inhibition for 1st line treatment in patients with G2 gliomas. Reduced seizure frequency aligns with our findings that mIDH inhibition modulates the glioma electrical microenvironment! 👇

121

Reposted by @braincancerlab.bsky.social

WEHI (The Walter and Eliza Hall Institute of Medical Research) @wehi-research.bsky.social · 22/08/2025

Researchers from WEHI, the Royal Melbourne Hospital & @petermaccc.bsky.social have achieved a brain cancer clinical trial world-first, providing hope to patients with low-grade gliomas. 🔗 www.wehi.edu.au/news/world-f...

The BrainPOP research team (left to right): Professor Kate Drummond, Dr Jim Whittle, Dr Saskia Freytag, Dr Sarah Best

1126

braincancerlab.bsky.social @braincancerlab.bsky.social · 22/08/2025

A central question in neuro-oncology is whether therapies penetrate the tumour and exert a biological effect. @jimwhittle.bsky.social and colleagues developed BrainPOP, a perioperative clinical trial platform and our lab had the pleasure of leading the translational research. 1/8

100